Relapsed or Refractory Classical Hodgkin's Lymphoma
Conditions
Brief summary
The study is a multi-center, prospective, non-interventional and observational study, and will collect data on the safety and efficacy of Tyvyt® in the treatment of Chinese patients with relapsed or refractory classical Hodgkin's lymphoma.
Interventions
None listed
Sponsors
Innovent Biologics (Suzhou) Co. Ltd.
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
Patients must be able to understand and voluntarily sign the informed consent form (ICF). Patients must provide reliable contact information, including home phone numbers or follow-up phone number, and be voluntary to be followed up. Patients must have agreed to use Tyvyt® to treat the target indication.
Exclusion criteria
Patients refuse to be included in the study or refuse to cooperate. Patients have participated in another interventional studies within 4 weeks prior to enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of known adverse drug reactions | During the actual Tyvyt treatment time. |
| Occurrence of new adverse drug reactions | During the actual Tyvyt treatment time. |
| Association, risk factors, severity and incidence of immune-related adverse drug reactions/events | During the actual Tyvyt treatment time. |
| Association, risk factors, severity and incidence of serious adverse drug reactions | During the actual Tyvyt treatment time. |
| Occurrence of adverse drug reactions in special population | During the actual Tyvyt treatment time. |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival (OS) | During the actual Tyvyt treatment time. |
Countries
China
Contacts
Primary ContactLei Zhao
Outcome results
None listed